

MATERIAL CHANGE REPORT

PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102

1. **Name and Address of Company:**

Miraculins Inc. (the "Company")
6 – 1250 Waverley Street
Winnipeg, Manitoba R3T 6C6

2. **Date of Material Change:**

February 14, 2012

3. **News Release:**

The Company issued a press release regarding the material change on February 14, 2012, a copy of which is attached hereto.

4. **Summary of Material Change:**

Miraculins announces that distinguished U.S. Cardiologist Dr. Henry A. Solomon, MD, FACP, FACC has been appointed to the PreVu Medical Advisory Board.

5. **Full Description Of Material Change:**

See attached Schedule "A".

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:**

Not Applicable.

7. **Omitted Information:**

Not Applicable.

8. **Executive Officer:**

Christopher Moreau, Chief Executive Officer
Tel: (204) 453-1408

DATED at Winnipeg, Manitoba this 14th day of February, 2012.

MIRACULINS INC.

Per: "Christopher Moreau"
Chris Moreau
President & CEO

SCHEDULE "A"

Miraculins Appoints Distinguished U.S. Cardiologist Dr. Henry Solomon to PreVu Medical Advisory Board

Former Chief Medical Officer of the American College of Cardiology
to Advise on U.S. Launch Strategy

WINNIPEG, Manitoba – February 14, 2012 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that distinguished U.S. Cardiologist Dr. Henry A. Solomon, MD, FACP, FACC has been appointed to the PreVu Medical Advisory Board.

Dr. Solomon received his MD from Columbia University College of Physicians and Surgeons (New York, NY), completed his internship and residency at Montefiore Hospital and Medical Centre (New York, NY), and his Cardiology Fellowship at the New York Hospital – Cornell Medical Center (New York, NY). He is a Diplomate of both the American Board of Internal Medicine and the American Board of Cardiovascular Disease. He was most recently the Chief Medical Officer, Business Development, of the American College of Cardiology, which has over 37,000 members including physicians, registered nurses, clinical nurse specialists, nurse practitioners, physician assistants, doctors of pharmacology and practice administrators specializing in cardiovascular care.

Dr. Solomon continues to serve as Senior Medical Advisor to the American College of Cardiology (which publishes the prestigious, peer reviewed *Journal of the American College of Cardiology*), as well as Chair of the College's Professional and Corporate Consortium. He is also a highly sought-after lecturer and medical guest commentator and has appeared on The Oprah Winfrey Show, ABC's 20/20 and Nightline, CBS's Face the Nation, and NBC's The Today Show.

"I am very pleased to become a member of the PreVu Medical Advisory Board," said Dr. Solomon. "The PreVu Non-Invasive Skin Cholesterol Test is a remarkable new risk assessment technology to assist in the earlier detection and primary prevention of coronary artery disease. It provides further risk stratification against the traditional determination of 'global risk', and can consequently help better identify patients with subclinical cardiovascular disease who could benefit from more intensive primary prevention measures to prevent a first coronary event."

"Dr. Solomon is a distinguished American Cardiologist, Researcher and medical mind," said Christopher J. Moreau, President and CEO of Miraculins. "His years of experience across the cardiology spectrum will help guide us as we introduce PreVu to world markets and work to educate Health Care Professionals everywhere about this significant new biomarker and the test designed to measure it. His experience will also be especially valuable as we take steps to strategically introduce PreVu into the U.S. marketplace and we will be updating the market shortly regarding our American sales and marketing plans."

About Dr. Henry A. Solomon

Dr. Henry A. Solomon's current and past affiliations include memberships in the American Medical Association; the American Heart Association; the New York State Medical Society; the New York Country Medical Society; the Royal Society of Medicine (Affiliate, London); the American Federation for Clinical Research; and the American Society of Hypertension. He is a Clinical Associate Professor of Medicine at The Weill Cornell Medical College of Cornell University in New York, and is additionally a Fellow of the American College of Physicians and the American College of Cardiology.

A highly published researcher and prolific author, Dr. Solomon has also served as Chairman of the Editorial Board of *Masters in Cardiology*, 1983-1996; as Editor-in-Chief of *Management Options in Cardiology*, 1989; as Editor-in-Chief of *Living with Angina*, 1981-1983; as Editor-in-Chief of *Cardiology Counterpoint*, 1981-1985; and has served on the Editorial Board of *The American Journal of Sports & Medicine*. He is the author of a best-selling book, "The Exercise Myth", which has been translated into several languages and sold in many countries.

Dr. Solomon possesses additional academic and medical credits far too numerous to detail in this forum and has been listed in the prestigious "Guide to America's Top Cardiologists".

About The PreVu Non-Invasive Skin Cholesterol Test

PreVu is a non-invasive risk assessment technology that evaluates the additional risk a person may have for coronary artery disease (CAD) by conveniently and painlessly testing their skin cholesterol level. High levels of skin cholesterol have been shown to be correlated to CAD as measured by stress test, angiography, coronary calcium, and carotid intima-media thickness, inflammatory markers of vascular disease, previous heart attack incidents and Framingham risk score.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on acquiring and advancing non-invasive tests for unmet clinical needs. The Company's PreVu test is a revolutionary new coronary artery disease (CAD) risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. The PreVu Non-Invasive Skin Cholesterol Point of Care (POC) Test technology has been cleared for sale by Health Canada and CE-Marked and Registered in the European Union. PreVu has previously been successfully test marketed in North America on a limited basis. Miraculins additional programs include a research use only ELISA kit for the detection of PSP94; and a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The Company's preeclampsia program is being advanced in partnership with Alere, Inc. (NYSE:ALR) (formerly known as Inverness Medical Innovations), one of the world's largest diagnostic companies.

For more information, please contact:

Christopher J. Moreau
President and CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1546

info@miraculins.com
www.miraculins.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to

expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

© PreVu is a registered trademark of Miraculins Inc. All Rights Reserved. 2011.